Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
L412553-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $39.90 | |
L412553-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,241.90 | |
L412553-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $59.90 | |
L412553-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $589.90 | |
L412553-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $939.90 |
Synonyms | LUT014|2274819-46-2|LUT-014|N5-(3-(7H-Purin-6-yl)pyridin-2-yl)-6-methyl-N1-(3-(trifluoromethoxy)phenyl)isoquinoline-1,5-diamine|T4E4I523RY|6-methyl-5-N-[3-(7H-purin-6-yl)pyridin-2-yl]-1-N-[3-(trifluoromethoxy)phenyl]isoquinoline-1,5-diamine|1,5-Isoquinoli |
---|---|
Specifications & Purity | ≥97% |
Biochemical and Physiological Mechanisms | LUT014 is an inhibitor of B-Raf with IC50 of 11.7 nM, and reduces dose-limiting acneiform lesions associated with EGFR Inhibitors treatment. |
Storage Temp | Protected from light,Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of B-Raf proto-oncogene; serine/threonine kinase |
Product Description | Information LUT014 is an inhibitor of B-Raf with IC50 of 11.7 nM, and reduces dose-limiting acneiform lesions associated with EGFR Inhibitors treatment. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 6-methyl-5-N-[3-(7H-purin-6-yl)pyridin-2-yl]-1-N-[3-(trifluoromethoxy)phenyl]isoquinoline-1,5-diamine |
---|---|
INCHI | InChI=1S/C27H19F3N8O/c1-15-7-8-19-18(9-11-32-24(19)37-16-4-2-5-17(12-16)39-27(28,29)30)21(15)38-25-20(6-3-10-31-25)22-23-26(35-13-33-22)36-14-34-23/h2-14H,1H3,(H,31,38)(H,32,37)(H,33,34,35,36) |
InChi Key | FZPYULHBUBXPIG-UHFFFAOYSA-N |
Canonical SMILES | CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC(=CC=C3)OC(F)(F)F)NC4=C(C=CC=N4)C5=C6C(=NC=N5)N=CN6 |
Isomeric SMILES | CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC(=CC=C3)OC(F)(F)F)NC4=C(C=CC=N4)C5=C6C(=NC=N5)N=CN6 |
PubChem CID | 138319775 |
Molecular Weight | 528.49 |
PubChem CID | 138319775 |
---|---|
CAS Registry No. | 2274819-46-2 |
Enter Lot Number to search for COA:
Sensitivity | Light sensitive |
---|
Starting at $241.90
Starting at $147.90
Starting at $23.90
Starting at $137.90
Starting at $42.90
Starting at $241.90
Starting at $118.90
1. Li T, Perez-Soler R. (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors.. Target Oncol, 4 (2): (107-19). [PMID:19452131] |
2. Lacouture ME, Wainberg ZA, Patel AB, Anadkat MJ, Stemmer SM, Shacham-Shmueli E, Medina E, Zelinger G, Shelach N, Ribas A. (2021) Reducing skin toxicities from EGFR inhibitors with topical BRAF inhibitor therapy.. Cancer Discov, 129 (3): (589-97). [PMID:33910927] |